Thiamine Intervention and Coronary Artery Bypass Grafting

About

Brief Summary

The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.

Primary Purpose

Treatment

Study Type

Interventional

Phase

Early Phase 1

Eligibility

Gender

All

Healthy Volunteers

No

Minimum Age

60 Years

Maximum Age

80 Years

Inclusion Criteria:

Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)
Thiamine deficiency before CABG
European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) >1.5%
Off-pump surgery

Exclusion Criteria:

Dementia at baseline [Montreal Cognitive Assessment (MoCA) <21 within 5 days before CABG]
Current in-take of thiamine
Known thiamine allergy
Uncontrolled blood glucose levels
Unable to give consent due to illness
History of hyperlactatemia
Recent (within several years and/or up to the judgment of the PI/co-PIs) cerebral incidents (seizure or head trauma resulting in loss of consciousness and/or concussion)
Stroke
Diagnosed psychiatric diseases (clinical depression, schizophrenia, manic-depression)
Patients with history of alcohol or substance abuse
Acute or chronic infections (tuberculosis, hepatitis, or encephalopathy)
Diagnosed neuro-degenerative diseases (Alzheimer's or Parkinson's disease)
Chronic immunodeficiency (including HIV)
Congenital brain deficits will also be excluded